Get an update on important issues impacting life sciences, pharma, and biotech companies. This conference is planned by the PICPA.
DESIGNED FOR
CPAs serving small and medium size life sciences, pharma, and biotech companies.
BENEFITS
To provide insight on accounting best practices, regulatory updates, and financial strategies for CPAs serving small and medium size life science, pharma, and biotech companies.
HIGHLIGHTS
7:45 a.m.
Greetings from PICPA Leadership
8- 8:50 a.m
State of the Industry
Christopher Molineaux, President & Chief Executive Officer, Life Sciences PA
- Impact of COVID-19 on the life sciences, pharmaceutical, and biotech industries.
- Changing dynamics of product portfolios.
- How to create value in the market for patients and for your workforce.
- Innovative finance strategies for innovative products and therapies.
8:50-9:40 a.m.
R&D Tax Considerations
Brandon Beller, CPA, Regional Director, Business Development, KBKG, Paul McVoy, Director, Research and Development Tax Credit Services, KBKG and Mike Kniss
Manager, Research and Development Tax Credit Services, KBKG
- COVID-19 legislation and its impact on the economy.
- Employee retention and research credits.
- Net operating loss carryback.
9:40-9:55 a.m.
Morning Break
9:55-11:35 a.m.
Funding Strategies and Best Practices
Daniel Geffken, Managing Director, Danforth Advisors LLC, Ricky Gross, Senior Manager: Audit and Assurance, Deloitte, Derek Gillespie, Partner, Deloitte, Barb Carlin, Managing Director: Mid-Atlantic Region, Danforth Advisors and Mark Hanulak, Senior Manager, Deloitte
- Overview of the venture capital landscape.
- IPOs, including their use as an exit or financing event.
- Alternative funding options: equity, grants, and mergers and acquisitions.
11:35-12:25 p.m.
Lunch Break
12:25-1:15 p.m.
Regulatory Updates
Doug Lauckhardt, Managing Director, Grant Thornton LLP and Andrew Taylor, Director, Grant Thornton LLP
- Price transparency and disclosure requirements.
- Digital health technology and cybersecurity considerations.
- Compliance considerations related to deals, manufacturing, and distribution.
- Impact of renewed public interest in how life science companies are operating.
1:15-2:05 p.m.
Revenue Accounting within the Pharmaceutical and Life Sciences Industry
Nick Lubold, CPA, Manager, Audit and Assurance, Deloitte
- Gross to Net (GTN) foundational concepts.
- Role of data analytics.
- Focus on profitability.
2:05-2:20 p.m.
Afternoon Break
2:20-3:10 p.m.
Collaborative Arrangements
Morgan Miles, CPA, Senior Manager, Accounting and Reporting Advisory, Deloitte
- Costs and risks of collaborating with third parties.
- What activities make up collaborative arrangements?
- How arrangements vary in scope, terms, and conditions.
- Risk mitigation considerations.
3:10-4 p.m.
Capitalization and Impairment
Chris Hudson, Assurance Partner, PwC and Alex Raymond, Assurance Director, PwC
- Internal development costs related to timing and regulatory approval.
- Development costs and expenditures.
- Indicators of impairment, including intangibles, property, plant, and equipment.
- Impairment testing and useful life.
COURSE LEVEL
Intermediate